Last reviewed · How we verify
SAM-e
At a glance
| Generic name | SAM-e |
|---|---|
| Also known as | 1 Experimental |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- S-Asenosyl-L-Methionine vs Placebo for Osteoarthritis of the Hands (PHASE4)
- Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults (PHASE1)
- Evaluation of the Safety and Pharmacokinetics of MSI-195 to a Commercial S-Adenosylmethionine (PHASE1)
- Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children (NA)
- SAM-e for the Treatment of Depression in Patients With Parkinson's Disease (PHASE2, PHASE3)
- A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease (PHASE2)
- Efficacy of S-Adenosylmethionine in Fibromyalgia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAM-e CI brief — competitive landscape report
- SAM-e updates RSS · CI watch RSS
- NYU Langone Health portfolio CI